Candriam Luxembourg S.C.A. purchased a new position in United Therapeutics Co. (NASDAQ:UTHR) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 2,800 shares of the biotechnology company’s stock, valued at approximately $358,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sun Life Financial INC bought a new stake in United Therapeutics during the 2nd quarter valued at $198,000. Advisor Partners LLC bought a new stake in United Therapeutics during the 3rd quarter valued at $201,000. Unison Advisors LLC bought a new stake in United Therapeutics during the 3rd quarter valued at $224,000. Balasa Dinverno & Foltz LLC bought a new stake in United Therapeutics during the 3rd quarter valued at $260,000. Finally, IFM Investors Pty Ltd bought a new stake in United Therapeutics during the 3rd quarter valued at $301,000. 93.69% of the stock is currently owned by institutional investors and hedge funds.
In other news, Director Christopher Causey sold 810 shares of United Therapeutics stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $118.00, for a total transaction of $95,580.00. Following the transaction, the director now directly owns 3,925 shares in the company, valued at approximately $463,150. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 8.20% of the stock is currently owned by company insiders.
Shares of UTHR stock opened at $115.17 on Monday. United Therapeutics Co. has a 1 year low of $100.57 and a 1 year high of $152.55. The firm has a market cap of $5.02 billion, a PE ratio of 10.58, a PEG ratio of 26.88 and a beta of 1.23. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.05 and a current ratio of 4.32.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.23 by ($0.81). United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The firm had revenue of $412.70 million for the quarter, compared to analyst estimates of $378.22 million. During the same quarter last year, the business posted $4.69 earnings per share. The firm’s revenue for the quarter was down 7.4% compared to the same quarter last year. As a group, research analysts expect that United Therapeutics Co. will post 14.28 earnings per share for the current year.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading: How dollar cost averaging works
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.